Plant Name: Calophyllum inophyllum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.248E-14 | 2.448E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.808E-12 | 4.920E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.570E-12 | 4.920E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.587E-12 | 5.841E-09 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.987E-12 | 5.913E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.665E-12 | 1.192E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.517E-11 | 1.159E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.212E-09 | 1.099E-06 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.025E-08 | 3.546E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, RAB9A |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.642E-08 | 3.806E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.322E-07 | 2.759E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.803E-07 | 3.862E-04 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.463E-06 | 6.501E-04 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.924E-06 | 1.202E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.872E-06 | 1.829E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.305E-06 | 2.651E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.022E-05 | 3.649E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.363E-05 | 4.636E-03 | CYP1A1, CYP1A2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.171E-05 | 7.272E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, MAOA, NPC1, RAB9A |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.738E-16 | 1.685E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.153E-11 | 4.037E-10 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.374E-10 | 5.904E-09 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.066E-10 | 7.077E-09 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.241E-10 | 7.211E-09 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.100E-09 | 7.698E-09 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.353E-08 | 6.765E-08 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.532E-09 | 2.060E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.552E-07 | 1.992E-06 | CYP2C9; MAOA; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.249E-06 | 2.041E-05 | CYP1A1; CYP1B1; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.949E-05 | 2.082E-04 | CYP2C9; MAOA; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.400E-04 | 2.673E-03 | CYP2C9; CYP2C19 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 1.667E-02 | 4.169E-02 | MAOA |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 1.184E-02 | 3.187E-02 | MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.495E-03 | 1.020E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |